Skip to main content
Log in

A Comparative Review of the Tolerability Profiles of Dopamine Agonists in the Treatment of Hyperprolactinaemia and Inhibition of Lactation

  • Review Articles
  • Drug Experience
  • Published:
Drug Safety Aims and scope Submit manuscript

An Erratum to this article was published on 01 May 1996

Summary

Dopamine agonists are the treatment of choice for the majority of patients with hyperprolactinaemic disorders. Although characterised by a relatively high incidence of adverse effects, most commonly gastrointestinal, cardiovascular and neurological, these are usually mild and transient, and can be minimised by starting with a low dose and gradually increasing it, or taking the drug with food or while recumbent.

Bromocriptine, introduced in 1971, is the reference preparation against which newer dopamine agonists are compared. It is effective in suppressing prolactin secretion, reducing prolactinoma size and restoring gonadal function. However, up to 12% of patients cannot tolerate the drug at therapeutic dosages.

Cabergoline, a long-acting dopamine agonist administered once or twice weekly, has been shown to be significantly more effective than bromocriptine in suppressing prolactin secretion in hyperprolactinaemic patients, and is better tolerated, particularly in terms of nausea and vomiting. In suppressing physiological lactation, cabergoline is at least as effective as bromocriptine, and is associated with significantly fewer rebound symptoms and adverse effects.

Quinagolide is a non-ergot dopamine agonist that is administered once daily. It has similar efficacy to bromocriptine, but is probably less effective than cabergoline in hyperprolactinaemic patients; it is not licensed for suppression of lactation. It is better tolerated than twice-daily bromocriptine, but is probably inferior to cabergoline in this regard.

Neither bromocriptine, cabergoline nor quinagolide has been associated with any detrimental effect on pregnancy or fetal development. However, experience with bromocriptine is far more extensive; thus, for women requiring treatment for subfertility, this drug remains the treatment of choice in most centres, with cabergoline and quinagolide as acceptable second-line drugs in bromocriptineintolerant patients. In hyperprolactinaemic men, hyperprolactinaemic women not wishing to become pregnant, and for suppression of physiological lactation, cabergoline is recommended as first-line treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Lloyd HM, Meares JD, Jacobi J. Effects of oestrogen and bromocriptine on in vivo secretion and mitosis in prolactin cells. Nature 1975; 255: 497–8

    Article  PubMed  CAS  Google Scholar 

  2. Barrow DL, Tindall GT, Kovacs K, et al. Clinical and pathological effects of bromocriptine on prolactin-secreting and other pituitary tumours. J Neurosurg 1984; 60: 1–7

    Article  PubMed  CAS  Google Scholar 

  3. Ho KY, Thorner MO. Therapeutic applications of bromocriptine in endocrine and neurological diseases. Drugs 1988; 36: 67–82

    Article  PubMed  CAS  Google Scholar 

  4. Crosignani PG, Ferrari C. Dopaminergic treatments for hyperprolactinaemia. Clin Obstet Gynaecol 1990; 4: 441–55

    CAS  Google Scholar 

  5. Molitch ME. Management of prolactinomas. Ann Rev Med 1989; 41: 255–32

    Google Scholar 

  6. Bevan JS, Webster J, Burke CW, et al. Dopamine agonists and pituitary tumor shrinkage. Endocrine Rev 1992; 13: 220–40

    CAS  Google Scholar 

  7. Lamberts SW, Quik RF. A comparison of the efficacy and safety of pergolide and bromocriptine in the treatment of hyperprolactinemia. J Clin Endocrinol Metab 1991; 72: 635–41

    Article  PubMed  CAS  Google Scholar 

  8. Mattox JH, Bernstein J, Buckman MT. Control of hyperprolactinemia with pergolide. Int J Fertil 1986; 30: 39–43

    PubMed  CAS  Google Scholar 

  9. Bouloux PM, Besser GM, Grossman A, et al. Clinical evaluation of lysuride in the management of hyperprolactinaemia. BMJ 1987; 294: 1323–4

    Article  PubMed  CAS  Google Scholar 

  10. Venturini PL, Horowski R, Fasce V, et al. Suppression of puerperal lactation by terguride: a double-blind study. Gynecol Obstet Invest 1988; 19: 225–9

    Google Scholar 

  11. Caballero Snr A, Mena P, Caballero-Ciaz JL, et al. Metergoline as an inhibitor of prolactin release. J Reprod Med 1987; 32: 115–9

    Google Scholar 

  12. de Aloysio D, Pamparana F, Zanotti A, et al. Dihydroergocristine in stopping lactation: double-blind study vs bromocriptine. Gynecol Endocrinol 1988; 2: 67–71

    Article  PubMed  Google Scholar 

  13. Ciccarelli E, Mazza E, Ghigo E, et al. Long term treatment with oral single administration of bromocriptine in patients with hyperprolactinemia. J Endocrinol Invest 1987; 10: 51–3

    PubMed  CAS  Google Scholar 

  14. Dutz W. Drugs stimulating dopamine receptors. In: Dukes MNG, editor. Meylers side effects of drugs, an encyclopaedia of adverse reactions and interactions. 12th ed. Amsterdam: Elsevier, 1992 317–8

    Google Scholar 

  15. Katzung BG. Basic and clinical pharmacology. 6th ed. East Norwalk (CT): Prentice-Hall International, 1995 424–5

    Google Scholar 

  16. Reynolds JEF. Dopaminergic antiparkinsonian agents. In: Martindale, the extra pharmacopoeia. 30th ed. London: Pharmaceutical Press, 1993 836–50

    Google Scholar 

  17. Parkes D. Side effects of bromocriptine. N Engl J Med 1980; 302: 749–50

    Article  Google Scholar 

  18. Webster J, Piscitelli G, Polli A, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinaemic amenorrhoea. N Engl J Med 1994; 331: 904–9

    Article  PubMed  CAS  Google Scholar 

  19. Eickman FM. Recurrent myocardial infarction in a postpartum patient receiving bromocriptine. Clin Cardiol 1992; 15: 781–3

    Article  PubMed  CAS  Google Scholar 

  20. Postpartum hypertension, seizures, strokes reported with bromocriptine. FDA Drug Bull 1984; 14: 3

    Google Scholar 

  21. Bromocriptine [news in brief]. Lancet 1993; 342: 675

    Google Scholar 

  22. Vlissides DN, Gill D, Castelow J. Bromocriptine-induced mania? BMJ 1978; I: 735–7

    Google Scholar 

  23. Pearson KC. Mental disorders from low-dose bromocriptine. N Engl J Med 1981; 305: 173

    PubMed  CAS  Google Scholar 

  24. Marshall AW, Jakobovits AW, Morgan MY. Bromocriptineassociated hyponatraemia in cirrhosis. BMJ 1982; 285: 1534–5

    Article  PubMed  CAS  Google Scholar 

  25. Giampietro O, Ferdeghini M, Petrini M. Severe leukopenia and mild thrombocytopenia after chronic bromocriptine (CB-154) administration. Am J Med Sci 1981; 281: 169–72

    Article  PubMed  CAS  Google Scholar 

  26. Krupp P, Monka C. Bromocriptine in pregnancy: safety aspects. Klin Wochenschr 1987; 65: 823–7

    Article  PubMed  CAS  Google Scholar 

  27. Rains CP, Bryson HM, Fitton A. Cabergoline. A review of its pharmacological properties and therapeutic potential in the treatment of hyperprolactinaemia and inhibition of lactation. Drugs 1995; 49: 255–79

    Article  PubMed  CAS  Google Scholar 

  28. Ferrari C, Barbieri C, Caldara R, et al. Long-lasting prolactinlowering effect of cabergoline, a new dopamine agonist, in hyperprolactinemic patients. J Clin Endocrinol Metab 1986; 63: 941–5

    Article  PubMed  CAS  Google Scholar 

  29. Mattel AM, Ferrari C, Baroldi P, et al. Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients. J Clin Endocrinol Metab 1988; 66: 193–8

    Article  Google Scholar 

  30. Webster J, Piscitelli G, Polli A, et al. The efficacy and tolerability of cabergoline therapy in hyperprolactinaemic disorders: an open, uncontrolled multicentre study. Clin Endocrinol 1993; 39: 323–9

    Article  CAS  Google Scholar 

  31. Webster J, Piscitelli G, Polli A, et al. Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. Clin Endocrinol 1992; 37: 534–41

    Article  CAS  Google Scholar 

  32. Ciccarelli E, Giusti M, Miola C, et al. Effectiveness and tolerability of long-term treatment with cabergoline, a new longlasting ergoline derivative, in hyperprolactinemic patients. J Clin Endocrinol Metab 1989; 69: 725–8

    Article  PubMed  CAS  Google Scholar 

  33. Ferrari C, Paracchi A, Mattei AM, et al. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol 1992; 126: 489–94

    PubMed  CAS  Google Scholar 

  34. European Multicentre Study Group for Cabergoline in Lactation Inhibition. Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: randomised, double blind, multicentre study. BMJ 1991; 302: 1367–71

    Article  Google Scholar 

  35. Giorda G, de Vincentis S, Motta T, et al. Cabergoline versus bromocriptine in suppression of lactation after Cesarean delivery. Gynecol Obstet Invest 1991; 31: 93–6

    Article  PubMed  CAS  Google Scholar 

  36. Bhatt MH, Keenan SP, Fleetham JA, et al. Pleuropulmonary disease associated with dopamine agonist therapy. Ann Neurol 1991; 30: 613–6

    Article  PubMed  CAS  Google Scholar 

  37. Frans E, Dom R, Demedts M. Pleuropulmonary changes during treatment of Parkinson’s disease with a long-acting ergot derivative, cabergoline. Eur Respir J 1992; 5: 263–5

    PubMed  CAS  Google Scholar 

  38. Jones TH, Fraser RB. Cabergoline treated hyperprolactinaemia results in pregnancy in a bromocriptine intolerant patient after seventeen years of infertility. Br J Obstet Gynaecol 1994; 101: 349–50

    Article  CAS  Google Scholar 

  39. Page SR, Nussey SS. Cabergoline therapy of a large prolactinoma in a bromocriptine-intolerant patient. J Obstet Gynaecol 1989; 10: 156–7

    Article  Google Scholar 

  40. Data on file. Pharmacia-Upjohn

  41. Venetikou MS, Burrin JM, Woods CA, et al. Effects of two novel dopaminergic drugs, CV 205–502 and CQP 201–403, on prolactin and growth hormone secretion by human pituitary tumours in vitro. Acta Endocrinol 1987; 116: 287–92

    PubMed  CAS  Google Scholar 

  42. Rasmussen C, Bergh T, Wide L, et al. CV 205–502: A new longacting drug for inhibition of prolactin hypersecretion. Clin Endocrinol 1987; 26: 321–6

    Article  CAS  Google Scholar 

  43. Rasmussen C, Brownell J, Bergh T. Clinical response and prolactin concentration in hyperprolactinaemic women during and after treatment for 24 months with the new dopamine agonist, CV 205–502. Acta Endocrinol 1991; 125: 170–6

    PubMed  CAS  Google Scholar 

  44. Homburg R, West C, Brownell J, et al. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205–502, with bromocriptine in women with hyperprolactinaemia. Clin Endocrinol 1990; 32: 565–71

    Article  CAS  Google Scholar 

  45. Verhelst JA, Froud AL, Touzel R, et al. Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinaemia: a double blind study. Acta Endocrinol 1991; 125: 385–91

    PubMed  CAS  Google Scholar 

  46. Data on file. Sandoz UK

  47. van der Heijden PFM, de Wit W, Brownell J, et al. CV205–502, a new dopamine agonist, versus bromocriptine in the treatment of hyperprolactinaemia. Eur J Obs Gynecol Reprod Biol 1991; 40: 111–8

    Article  Google Scholar 

  48. Giusti M, Porcella E, Carraro A, et al. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinaemic patients. J Endocrinol Invest 1994; 17: 51–7

    PubMed  CAS  Google Scholar 

  49. Vilar L, Burke CW. Quinagolide efficacy and tolerability in hyperprolactinaemic patient who are resistant to or intolerant of bromocriptine. Clin Endocrinol 1994; 41: 821–6

    Article  CAS  Google Scholar 

  50. Newman CB, Hurley AM, Kleinberg DL. Effect of CV 205–502 in hyperprolactinaemic patients intolerant of bromocriptine. Clin Endocrinol 1989; 31: 391–400

    Article  CAS  Google Scholar 

  51. Barnett PS, Dawson JM, Butler J, et al. CV 205–502, a new non-ergot dopamine agonist, reduces prolactinoma size in man. Clin Endocrinol 1990; 33: 307–16

    Article  CAS  Google Scholar 

  52. Barnett PS, Palazidou E, Miell JP, et al. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV 205–502. Q J Med 1991; 295: 891–906

    Google Scholar 

  53. van der Lely AJ, Brownell J, Lamberts SWJ. The efficacy and tolerability of CV 205–502 (a nonergot dopaminergic drug) in macroprolactinoma patients and in prolactinoma patients intolerant to bromocriptine. J Clin Endocrinol Metab 1991; 72: 1136–41

    Article  PubMed  Google Scholar 

  54. Razzaq R, O’Halloran DJ, Beardwell CG, et al. The effects of CV 205–502 in patients with hyperprolactinaemia intolerant and/or resistant to bromocriptine. Horm Res 1993; 39: 218–22

    Article  PubMed  CAS  Google Scholar 

  55. Merola B, Sarnacchiaro F, Colao A, et al. Positive response to compound CV 205–502 in hyperprolactinaemic patients resistant to or intolerant of bromocriptine. Gynecol Endocrinol 1994; 8: 175–81

    Article  PubMed  CAS  Google Scholar 

  56. Grossman A, Bouloux PM, Loneragan R, et al. Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia. Clin Endocrinol 1985; 22: 611–6

    Article  CAS  Google Scholar 

  57. Berezin M, Avidan D, Baron E. Long-term pergolide treatment of hyperprolactinaemic patients previously unsuccessfully treated with dopaminergic drugs. Isr J Med Sci 1991; 27: 375–9

    PubMed  CAS  Google Scholar 

  58. Stracke H, Heinlein W, Horowski R, et al. Dopamine agonists in the treatment of hyperprolactinemia. Comparison between bromocriptine and lisuride. Arzneimittel Forschung 1986; 36: 1834–6

    PubMed  CAS  Google Scholar 

  59. Ciccarelli E, Touzel R, Besser M, et al. Terguride: a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine. Fertil Steril 1988; 49: 589–94

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/BF03258533.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Webster, J. A Comparative Review of the Tolerability Profiles of Dopamine Agonists in the Treatment of Hyperprolactinaemia and Inhibition of Lactation. Drug-Safety 14, 228–238 (1996). https://doi.org/10.2165/00002018-199614040-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-199614040-00003

Keywords

Navigation